PPAR Gamma in Neuroblastoma: The Translational Perspectives of Hypoglycemic Drugs

Serena Vella, Pier Giulio Conaldi, Tullio Florio, Aldo Pagano

Research output: Contribution to journalReview article

Abstract

Neuroblastoma (NB) is the most common and aggressive pediatric cancer, characterized by a remarkable phenotypic diversity and high malignancy. The heterogeneous clinical behavior, ranging from spontaneous remission to fatal metastatic disease, is attributable to NB biology and genetics. Despite major advances in therapies, NB is still associated with a high morbidity and mortality. Thus, novel diagnostic, prognostic, and therapeutic approaches are required, mainly to improve treatment outcomes of high-risk NB patients. Among neuroepithelial cancers, NB is the most studied tumor as far as PPAR ligands are concerned. PPAR ligands are endowed with antitumoral effects, mainly acting on cancer stem cells, and constitute a possible add-on therapy to antiblastic drugs, in particular for NB with unfavourable prognosis. While discussing clinical background, this review will provide a synopsis of the major studies about PPAR expression in NB, focusing on the potential beneficial effects of hypoglycemic drugs, thiazolidinediones and metformin, to reduce the occurrence of relapses as well as tumor regrowth in NB patients.

Original languageEnglish
Article number3038164
JournalPPAR Research
Volume2016
DOIs
Publication statusPublished - 2016

Fingerprint

PPAR gamma
Neuroblastoma
Hypoglycemic Agents
Peroxisome Proliferator-Activated Receptors
Neoplasms
Ligands
Spontaneous Remission
Thiazolidinediones
Neoplastic Stem Cells
Metformin
Therapeutics
Pediatrics
Morbidity
Recurrence
Mortality
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology (medical)

Cite this

PPAR Gamma in Neuroblastoma : The Translational Perspectives of Hypoglycemic Drugs. / Vella, Serena; Conaldi, Pier Giulio; Florio, Tullio; Pagano, Aldo.

In: PPAR Research, Vol. 2016, 3038164, 2016.

Research output: Contribution to journalReview article

@article{8a867abba2ee45b786b848c8517d19d9,
title = "PPAR Gamma in Neuroblastoma: The Translational Perspectives of Hypoglycemic Drugs",
abstract = "Neuroblastoma (NB) is the most common and aggressive pediatric cancer, characterized by a remarkable phenotypic diversity and high malignancy. The heterogeneous clinical behavior, ranging from spontaneous remission to fatal metastatic disease, is attributable to NB biology and genetics. Despite major advances in therapies, NB is still associated with a high morbidity and mortality. Thus, novel diagnostic, prognostic, and therapeutic approaches are required, mainly to improve treatment outcomes of high-risk NB patients. Among neuroepithelial cancers, NB is the most studied tumor as far as PPAR ligands are concerned. PPAR ligands are endowed with antitumoral effects, mainly acting on cancer stem cells, and constitute a possible add-on therapy to antiblastic drugs, in particular for NB with unfavourable prognosis. While discussing clinical background, this review will provide a synopsis of the major studies about PPAR expression in NB, focusing on the potential beneficial effects of hypoglycemic drugs, thiazolidinediones and metformin, to reduce the occurrence of relapses as well as tumor regrowth in NB patients.",
author = "Serena Vella and Conaldi, {Pier Giulio} and Tullio Florio and Aldo Pagano",
year = "2016",
doi = "10.1155/2016/3038164",
language = "English",
volume = "2016",
journal = "PPAR Research",
issn = "1687-4757",
publisher = "Hindawi Publishing Corporation",

}

TY - JOUR

T1 - PPAR Gamma in Neuroblastoma

T2 - The Translational Perspectives of Hypoglycemic Drugs

AU - Vella, Serena

AU - Conaldi, Pier Giulio

AU - Florio, Tullio

AU - Pagano, Aldo

PY - 2016

Y1 - 2016

N2 - Neuroblastoma (NB) is the most common and aggressive pediatric cancer, characterized by a remarkable phenotypic diversity and high malignancy. The heterogeneous clinical behavior, ranging from spontaneous remission to fatal metastatic disease, is attributable to NB biology and genetics. Despite major advances in therapies, NB is still associated with a high morbidity and mortality. Thus, novel diagnostic, prognostic, and therapeutic approaches are required, mainly to improve treatment outcomes of high-risk NB patients. Among neuroepithelial cancers, NB is the most studied tumor as far as PPAR ligands are concerned. PPAR ligands are endowed with antitumoral effects, mainly acting on cancer stem cells, and constitute a possible add-on therapy to antiblastic drugs, in particular for NB with unfavourable prognosis. While discussing clinical background, this review will provide a synopsis of the major studies about PPAR expression in NB, focusing on the potential beneficial effects of hypoglycemic drugs, thiazolidinediones and metformin, to reduce the occurrence of relapses as well as tumor regrowth in NB patients.

AB - Neuroblastoma (NB) is the most common and aggressive pediatric cancer, characterized by a remarkable phenotypic diversity and high malignancy. The heterogeneous clinical behavior, ranging from spontaneous remission to fatal metastatic disease, is attributable to NB biology and genetics. Despite major advances in therapies, NB is still associated with a high morbidity and mortality. Thus, novel diagnostic, prognostic, and therapeutic approaches are required, mainly to improve treatment outcomes of high-risk NB patients. Among neuroepithelial cancers, NB is the most studied tumor as far as PPAR ligands are concerned. PPAR ligands are endowed with antitumoral effects, mainly acting on cancer stem cells, and constitute a possible add-on therapy to antiblastic drugs, in particular for NB with unfavourable prognosis. While discussing clinical background, this review will provide a synopsis of the major studies about PPAR expression in NB, focusing on the potential beneficial effects of hypoglycemic drugs, thiazolidinediones and metformin, to reduce the occurrence of relapses as well as tumor regrowth in NB patients.

UR - http://www.scopus.com/inward/record.url?scp=84992391012&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84992391012&partnerID=8YFLogxK

U2 - 10.1155/2016/3038164

DO - 10.1155/2016/3038164

M3 - Review article

VL - 2016

JO - PPAR Research

JF - PPAR Research

SN - 1687-4757

M1 - 3038164

ER -